RIM
ABUS icon

RS Investment Management’s Arbutus Biopharma ABUS Stock Holding History

RS Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-972,540
Closed -$11.5M – 350
2015
Q2 		$11.5M Buy
972,540
+396,400
+69% +$6.03M 0.1% 240
2015
Q1 		$10.1M Buy
+576,140
New +$11.8M 0.09% 242

Other funds holding ABUS

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

RS Investment Management's ABUS Position: Q3 2015 in Review

RS Investment Management sold out of Arbutus Biopharma (ABUS) in Q3 2015, closing a stake of 972,540 shares — an estimated $11.5M sold.

RS Investment Management first reported a position in ABUS in Q1 2015 and held it in 2 quarters. The position peaked at $11.5M in Q2 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q3 2015.

  • RS Investment Management reported no remaining Arbutus Biopharma position as of Q3 2015 after selling out during the quarter.
  • RS Investment Management sold 972,540 Arbutus Biopharma shares in Q3 2015, an estimated $11.5M.
  • RS Investment Management first reported a position in Arbutus Biopharma in Q1 2015 and held it in 2 quarters.
  • RS Investment Management's Arbutus Biopharma position peaked at $11.5M in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2015.

Based on RS Investment Management's 13F filing for Q3 2015, filed 4 Nov 2015.